PlumX Metrics
Embed PlumX Metrics

Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century

Surgical Oncology Clinics of North America, ISSN: 1055-3207, Vol: 15, Issue: 1, Page: 159-173
2006
  • 10
    Citations
  • 0
    Usage
  • 10
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    10
    • Citation Indexes
      10
  • Captures
    10

Review Description

The most effective current regimen for adjuvant treatment of surgically resected stage III colon cancer is the FOLFOX regimen of oxaliplatin, 5-FU and LV for 12 weeks, with a proportional risk reduction of 45% compared with approximately 36% for 5-FU/LV regimens. Infusion regimens of 5-FU with and without LV have been shown to confer equivalent benefit to bolus regimens in reducing the risk of cancer recurrence, but with lesser toxicity profiles. Oral 5-FU prodrug regimens have similarly shown equivalent benefit to bolus regimens, and toxicity comparable to infusional regimens, but with the added convenience over 5-FU infusion therapy. The addition of irinotecan to 5-FU and LV regimens has not demonstrated an advantage compared with 5-FU/LV treatments in the adjuvant setting. © 2006 Elsevier Inc. All rights reserved.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know